Selective, User-friendly, Highly Porous, Efficient, and Rapid (SUPER) Filter for Isolation and Analysis of Rare Tumor Cells

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Kaifeng Zhao ◽  
Yaoping Liu ◽  
Hua Wang ◽  
Yanling Song ◽  
Xiao-Feng Chen ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Clinical Application ◽  
Liquid Biopsy ◽  
Body Fluids ◽  
Selective Separation ◽  
Rare Tumor ◽  
Filtration System ◽  
User Friendly ◽  
Highly Porous

Rapid, efficient, and selective separation of tumor cells from complex body fluids is urgently needed for clinical application of tumor-cell-based liquid biopsy. Herein, a size-selective affinity filtration system, named Selective,...

A high-throughput liquid biopsy for rapid rare cell separation from large-volume samples

Lab on a Chip ◽  
2019 ◽  
Vol 19 (1) ◽  
pp. 68-78 ◽  
Author(s):  
Yaoping Liu ◽  
Tingyu Li ◽  
Mingxin Xu ◽  
Wei Zhang ◽  
Yan Xiong ◽  
...  
Keyword(s):  
Tumor Cell ◽  
High Throughput ◽  
Cancer Detection ◽  
Large Volume ◽  
Liquid Biopsy ◽  
Cell Separation ◽  
Body Fluids ◽  
Rare Tumor

The developed high-throughput liquid biopsy platform for rare tumor cell separation from body fluids has shown enormous promise in cancer detection and prognosis monitoring.

A universal high-throughput liquid biopsy technique for rare tumor cells recovery from various body fluids.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e24224-e24224
Author(s):  
Yaoping Liu ◽  
Tingyu Li ◽  
Wei Zhang ◽  
Lianjun Lin ◽  
Xiaolong Rao ◽  
...  
Keyword(s):  
Tumor Cells ◽  
High Throughput ◽  
Liquid Biopsy ◽  
Body Fluids ◽  
Rare Tumor ◽  
Biopsy Technique

Cell free DNA as an evolving liquid biopsy biomarker for initial diagnosis and therapeutic nursing in Cancer- An evolving aspect in Medical Biotechnology

2020 ◽  
Vol 21 ◽  
Author(s):  
Suman Kumar Ray ◽  
Sukhes Mukherjee
Keyword(s):  
Tumor Cells ◽  
Liquid Biopsy ◽  
Cancer Metastasis ◽  
Nuclear Dna ◽  
Fragment Size ◽  
Body Fluids ◽  
Response To Therapy ◽  
Significant Information ◽  
Cell Free Dna ◽  
Free Dna

: Cell-free DNA (cfDNA) is present in numerous body fluids in addition to initiates generally from blood cells. It is undoubtedly the utmost promising tool among all components of liquid biopsy. Liquid biopsy is a specialized method investigating the nonsolid biological tissue by revealing of circulating cells, cell free DNA etc. that enter body fluids. Since, cancer cells disengage from compact tumors circulate in peripheral blood, evaluating blood of cancer patients holds the opportunities for capture and molecular level analysis of various tumor-derived constituents. Cell free DNA samples can deliver a significant perceptions into oncology, for instance tumor heterogeneity, instantaneous tumor development, response to therapy and treatment, comprising immunotherapy and mechanisms of cancer metastasis. Malignant growth at any phase can outhouse tumor cells in addition to fragments of neoplasticity causing DNA into circulatory system giving noble sign of mutation in the tumor at sampling time. Liquid biopsy distinguishes diverse blood based evolving biomarkers comprising circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) or cfDNA, circulating RNA (cfRNA) and exosomes. Cell free DNA are little DNA fragments found circulating in plasma or serum, just as other fluids present in our body. Cell free DNA involves primarily double stranded nuclear DNA and mitochondrial DNA, present both on a surface level and in the lumen of vesicles. The probable origins of the tumor-inferred portion of cfDNA are apoptosis or tumor necrosis, lysis of CTCs or release of DNA from the tumor cells into circulation. The evolution of innovations, refinement and improvement in therapeutics for determination of cfDNA fragment size and its distribution provide significant information related with pathological conditions of the cell, thus emerging as promising indicator for clinical output in medical biotechnology.

scholarly journals Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas

Diagnostics ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 192
Author(s):  
Leonie Konczalla ◽  
Anna Wöstemeier ◽  
Marius Kemper ◽  
Karl-Frederik Karstens ◽  
Jakob Izbicki ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Application ◽  
Liquid Biopsy ◽  
Cancer Diagnostics ◽  
Therapeutic Approaches ◽  
Primary Tumors ◽  
New Therapeutic Approaches ◽  
Tumor Dissemination

The idea of a liquid biopsy to screen, surveil and treat cancer patients is an intensively discussed and highly awaited tool in the field of oncology. Despite intensive research in this field, the clinical application has not been implemented yet and further research has to be conducted. However, one component of the liquid biopsy is circulating tumor cells (CTCs) whose potential for clinical application is evaluated in the following. CTCs can shed from primary tumors to the peripheral blood at any time point during the progress of a malignant disease. Following, one single CTC can be the origin for distant metastasis at later cancer stage. Thus, CTCs have great potential to either be used in cancer diagnostics and patient stratification or to function as a target for new therapeutic approaches to stop tumor dissemination and metastasis at the very early beginning. Due to the biological fundamental role of CTCs in tumor progression, here, we provide an overview of CTCs in gastrointestinal cancers and their potential use in the clinical setting. In particular, we discuss the usage of CTC for screening and stratifying patients’ risk. Moreover, we will discuss the potential role of CTCs for treatment specification and treatment monitoring.

Rethinking liquid biopsy: Microfluidic assays for mobile tumor cells in human body fluids

Biomaterials ◽  
2018 ◽  
Vol 150 ◽  
pp. 112-124 ◽  
Author(s):  
Kuang Hong Neoh ◽  
Ayon Ahmed Hassan ◽  
Anqi Chen ◽  
Yukun Sun ◽  
Peng Liu ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Human Body ◽  
Liquid Biopsy ◽  
Body Fluids ◽  
Microfluidic Assays

scholarly journals Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 888
Author(s):  
Taiji Kuwata ◽  
Kazue Yoneda ◽  
Masataka Mori ◽  
Masatoshi Kanayama ◽  
Koji Kuroda ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Malignant Pleural Mesothelioma ◽  
Circulating Tumor Cell ◽  
Microfluidic System ◽  
Clinical Implications ◽  
Pleural Mesothelioma ◽  
Rare Tumor ◽  
Podoplanin Expression ◽  
Higher Sensitivity

Circulating tumor cell (CTC) is a potentially useful surrogate of micro-metastasis, but detection of rare tumor cells contaminated in a vast majority of normal hematologic cells remains technical challenges. To achieve effective detection of a variety of CTCs, we have developed a novel microfluidic system (CTC-chip) in which any antibody to capture CTCs is easily conjugated. In previous studies, we employed an antibody (clone E-1) against podoplanin that was strongly expressed on mesothelioma cells. The CTC-chip coated by the E-1 antibody (E1-chip) provided a modest sensitivity in detection of CTCs in malignant pleural mesothelioma (MPM). Here, to achieve a higher sensitivity, we employed a novel anti-podoplanin antibody (clone NZ-1.2). In an experimental model, MPM cells with high podoplanin expression were effectively captured with the CTC-chip coated by the NZ-1.2 antibody (NZ1.2-chip). Next, we evaluated CTCs in the peripheral blood sampled from 22 MPM patients using the NZ1.2-chip and the E1-chip. One or more CTCs were detected in 15 patients (68.2%) with the NZ1.2-chip, whereas only in 10 patients (45.5%) with the E1-chip. Of noted, in most (92.3%, 12/13) patients with epithelioid MPM subtype, CTCs were positive with the NZ1.2-chip. The CTC-count detected with the NZ1.2-chip was significantly higher than that with the E1-chip (p = 0.034). The clinical implications of CTCs detected with the NZ1.2-chip will be examined in a future study.

Inertial Microfluidics for Separation and Detection of Tumor Cells

2013 ◽  
Author(s):  
Jiashu Sun
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Cell Separation ◽  
Microfluidic Channel ◽  
Isothermal Amplification ◽  
Rare Tumor ◽  
Label Free ◽  
Ck19 Mrna ◽  
Hydrodynamic Effects ◽  
Mcf 7

We report on the development of a curved microfluidic channel that allows rapid and continuous size-based rare tumor cell separation from blood in a label-free manner by exploiting the hydrodynamic effects. The separated tumor cells are trapped and enriched on an integrated polycarbonate filter glued on top of the outlet reservoir of microchannels. CK19 mRNA of MCF-7 cells are detected by loop-mediated isothermal amplification (LAMP).

Tumor cell communication through EVs: new challenges and opportunities

2019 ◽  
Vol 1 (1) ◽  
pp. 27-30
Author(s):  
Cecile L. Maire ◽  
Franz L. Ricklefs
Keyword(s):  
Tumor Growth ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Intercellular Communication ◽  
Liquid Biopsy ◽  
Cell Communication ◽  
Potential Utility ◽  
Challenges And Opportunities ◽  
New Challenges ◽  
Substantial Interest

Extracellular vesicles (EVs) are small, heterogeneous, lipid-bilayer particles that are potent vehicles of intercellular communication, contributing to the interaction of tumor cells with the microenvironment and promoting tumor growth. Furthermore, EVs have gained substantial interest due to their potential utility for liquid biopsy approaches in cancer.

Rapid and precise tumor cell separation using the combination of size-dependent inertial and size-independent magnetic methods

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Di Huang ◽  
Nan Xiang
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Tumor Antigen ◽  
Cell Separation ◽  
Stage I ◽  
Rare Tumor ◽  
Inertial Microfluidics ◽  
Size Dependent ◽  
Magnetic Methods

A three-stage i-Mag device combines the passive inertial microfluidics and the active magnetophoresis method for rapid, precise, and tumor antigen-independent separation of rare tumor cells from blood.

Interaction of Human Tumor Cells with Human Platelets and the Coagulation System

1983 ◽  
Vol 50 (03) ◽  
pp. 726-730 ◽  
Author(s):  
Hamid Al-Mondhiry ◽  
Virginia McGarvey ◽  
Kim Leitzel
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Cell Lines ◽  
Human Tumor ◽  
Human Platelets ◽  
Factor Vii ◽  
Coagulation System ◽  
Breast Adenocarcinoma ◽  
Activate Factor ◽  
Tumor Cell Lines

SummaryThis paper reports studies on the interaction between human platelets, the plasma coagulation system, and two human tumor cell lines grown in tissue culture: Melanoma and breast adenocarcinoma. The interaction was monitored through the use of 125I- labelled fibrinogen, which measures both thrombin activity generated by cell-plasma interaction and fibrin/fibrinogen binding to platelets and tumor cells. Each tumor cell line activates both the platelets and the coagulation system simultaneously resulting in the generation of thrombin or thrombin-like activity. The melanoma cells activate the coagulation system through “the extrinsic pathway” with a tissue factor-like effect on factor VII, but the breast tumor seems to activate factor X directly. Both tumor cell lines activate platelets to “make available” a platelet- derived procoagulant material necessary for the conversion of prothrombin to thrombin. The tumor-derived procoagulant activity and the platelet aggregating potential of cells do not seem to be inter-related, and they are not specific to malignant cells.

Sign in / Sign up

Export Citation Format

Share Document